FY2025 Earnings Forecast for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Issued By Capital One Financial

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Capital One Financial boosted their FY2025 earnings estimates for shares of Ironwood Pharmaceuticals in a report issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now expects that the biotechnology company will earn $0.88 per share for the year, up from their previous estimate of $0.85. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.71 per share.

Several other analysts also recently weighed in on the company. Craig Hallum initiated coverage on Ironwood Pharmaceuticals in a report on Wednesday, January 17th. They issued a “buy” rating and a $21.00 target price for the company. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Wells Fargo & Company reduced their price target on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. Finally, Piper Sandler raised their price objective on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $19.80.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $8.12 on Friday. The firm has a fifty day moving average price of $8.82 and a 200 day moving average price of $10.60. The stock has a market cap of $1.27 billion, a PE ratio of -1.25 and a beta of 0.57. Ironwood Pharmaceuticals has a 1-year low of $7.53 and a 1-year high of $15.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter worth $33,281,000. Jacobs Levy Equity Management Inc. purchased a new stake in Ironwood Pharmaceuticals during the third quarter worth about $22,903,000. Jupiter Asset Management Ltd. grew its position in Ironwood Pharmaceuticals by 566.8% during the third quarter. Jupiter Asset Management Ltd. now owns 2,210,985 shares of the biotechnology company’s stock worth $21,292,000 after buying an additional 1,879,401 shares during the period. Adage Capital Partners GP L.L.C. increased its holdings in Ironwood Pharmaceuticals by 160.9% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,462,300 shares of the biotechnology company’s stock valued at $23,712,000 after buying an additional 1,518,500 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Ironwood Pharmaceuticals by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 16,033,545 shares of the biotechnology company’s stock valued at $183,424,000 after acquiring an additional 1,137,845 shares during the period.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, SVP Andrew Davis sold 9,846 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the completion of the transaction, the senior vice president now owns 208,324 shares in the company, valued at approximately $3,174,857.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, SVP Andrew Davis sold 9,846 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the transaction, the senior vice president now directly owns 208,324 shares in the company, valued at $3,174,857.76. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jon R. Duane acquired 6,920 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of $8.70 per share, with a total value of $60,204.00. Following the transaction, the director now owns 121,028 shares of the company’s stock, valued at $1,052,943.60. The disclosure for this purchase can be found here. Insiders sold a total of 273,008 shares of company stock valued at $4,160,642 over the last three months. 13.10% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.